Inactief instrument

Andere talen EQRx, Inc.

Aandelen

EQRX

US26886C1071

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Revolution Medicines Closes Acquisition of EQRx in All-Stock Deal	09/11
EQRx, Inc. Announces Board Resignations	09/11
EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Composite Index	09/11
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Global BMI Index	09/11
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Biotechnology Select Industry Index	09/11
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P TMI Index	09/11
Revolution Medicines, Inc. completed the acquisition of EQRx, Inc. from a group of shareholders.	09/11
Revolution Medicines, EQRx Stockholders Approve Merger	08/11
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition	08/11
EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Biotechnology Index	08/11
EQRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11
Calling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses	26-10-23
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX	06-10-23
EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders	27-09-23
EQRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08-08-23
Hansoh Pharmaceutical Terminates License Agreement With EQRx for Aumolertinib; Shares Slump 10%	07-08-23
EQRx : Termination of Material Agreement - Form 8-K	03-08-23
EQRx, Inc. Provides Written Notice to G1 Therapeutics of its Termination of the Exclusive License Agreement	03-08-23
EQRx, Inc. Provides Written Notice to Hansoh Healthtech Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Ltd. of Its Termination of the Strategic Collaboration License Agreement	03-08-23
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX	03-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen EQRx, Inc.

Aandelen

EQRX

US26886C1071

Andere talen

Filters